FindTrial
Sign In

ozanimod placebo

DRUG3 trials

Sponsors

Celgene

Conditions

Healthy VolunteerHealthy VolunteersRelapsing Multiple Sclerosis

Phase 1

Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate
CompletedNCT03644576
CelgeneHealthy Volunteers
Start: 2018-07-11End: 2018-09-12Updated: 2019-05-30
Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response
CompletedNCT03694119
CelgeneHealthy Volunteer
Start: 2018-07-24End: 2019-01-08Updated: 2019-07-19

Phase 3

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
CompletedNCT02047734
CelgeneRelapsing Multiple Sclerosis
Start: 2013-12-03End: 2017-04-13Updated: 2021-02-11

Related Papers

Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials
European Journal of Neurology2025-06-011 citations
Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis.
2025-04-012 citations
Monitoramento do Horizonte Tecnológico: Ozanimode para o tratamento da esclerose múltipla
Jornal de Assistência Farmacêutica e Farmacoeconomia2024-11-30
Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons
Journal of Comparative Effectiveness Research2024-08-192 citations
Absolute Lymphocyte Count Around Infections During Phase 3 and Open-label Extension Trials of Ozanimod in Participants with Relapsing Multiple Sclerosis (P10-6.013)
Neurology2024-04-09
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial
Multiple Sclerosis Journal2023-12-214 citations
Relationship Between Infections and Absolute Lymphocyte Count During Phase 3 and Open-label Extension Trials of Ozanimod in Patients With Relapsing Multiple Sclerosis (P7-3.002)
Neurology2023-04-25
Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis (P5-3.010)
Neurology2023-04-25
2221 Evaluating no evidence of disease activity (NEDA) with Ozanimod in patients with relapsing multiple sclerosis (RMS): post hoc analysis of phase 3 RADIANCE and DAYBREAK
Abstracts2022-08-01
P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
The American Journal of Gastroenterology2021-12-017 citations
067 Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials
2021-08-012 citations
Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects.
2020-10-0617 citations
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
2019-09-03192 citations
Gray Matter Volume Loss Is Increased in Younger Patients With Relapsing Multiple Sclerosis but Minimized by Ozanimod: Experience From the Ozanimod Phase 3 Program (P5.2-056)
Neurology2019-04-09
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
Multiple Sclerosis Journal2018-07-2549 citations
Safety of Ozanimod Versus Interferon β-1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.006)
Neurology2018-04-105 citations
Efficacy Results of the Phase 2 Portion of the RADIANCE Trial: A Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 in Adults with Relapsing Multiple Sclerosis (P7.198)
Neurology2015-04-065 citations
Safety and Tolerability Results of the Phase 2 Portion of the RADIANCE Trial: A Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 in Relapsing Multiple Sclerosis (P7.199)
Neurology2015-04-061 citations